百利天恒 (02615)今日起至下周三(11月12日)招股，发售863.43万股H股，香港公开发售占10%，国际配售占90%；每股招股价介乎347.5港元至389港元，集资最多33.59亿元。
申购阶梯：
一手100股，入场费39292.31港元。
该公司拟将所得款项净额中，约60%用于拨付中国内地以外地区的候选生物药物的研发活动；约30%用于建立全球供应链；及约10%用于拨付在中国内地以外业务的营运资金及其他一般公司用途。
该股预期11月17日挂牌买卖。联席保荐人包括高盛、摩根大通及中信証券。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.